deucravacitinib, Placebo to match BMS 986165 tablet
IM011-075
Phase 3 small_molecule active
Quick answer
deucravacitinib, Placebo to match BMS 986165 tablet for Moderate-to-Severe Plaque Psoriasis is a Phase 3 program (small_molecule) at Bristol-Myers Squibb / Pfizer EEIG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Bristol-Myers Squibb / Pfizer EEIG
- Indication
- Moderate-to-Severe Plaque Psoriasis
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active